Diagnostic role of soluble Fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: A pilot study

Acta Dermato-Venereologica

Volumn 86, Issue 3, 2006, Pages 215-218

  Lan, Cheng Che E ^a   Wu, Ching Shuang ^b   Tsai, Pei Chien ^b   Chen, Gwo Shing ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Peripheral blood mononuclear cell; Soluble Fas ligand; Stevens Johnson syndrome; Toxic epidermal nercolysis

Indexed keywords

CARBAMAZEPINE; FAS LIGAND;

ADULT; ARTICLE; BLISTER; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; CARBAMAZEPINE; EPIDERMAL NECROLYSIS, TOXIC; FAS LIGAND PROTEIN; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTORS;

EID: 33745017478     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0074     Document Type: Article

References (17)

1. Roujeau JC, Guillaume JC, Fahre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome) incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37-42.
2. Roujeau JC, Chosidow O, Siag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-1058.
3. Hertl M, Merk HF. Lymphocyte acrivation in cutaneous drug reactions. J Invest Dermatol 1995; 105: 95-98.
4. Romano A, Torres MJ, Quaratino D, Di Fonso M, Perrone MR, Viola M, et al. Diagnostic evaluation of delayed hypersensitivity to systemically administered drugs. Allergy 1999; 54: 23-27.
5. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27: 175-181.
6. Merk HF. Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. Toxicology 2005; 209: 217-220.
7. Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Forster J, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207: 96-99.
8. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobuiin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-255.
9. Becker DS. Toxic epidermal necrolysis. Lancet 1998; 351: 1417-1420.
10. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28-30.
11. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
12. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162: 1515-1520.
13. Yu CL, Chang KL, Chiu CC, Chiang BN, Han SH, Wang SR. Alteration of mitogenic responses of mononuclear cells by anti-ds DNA antibodies resembling immune disorders in patients with systemic lupus erythematosus. Scand J Rheumatol 1989; 18: 43-49.
14. Sachs B, Erdmann S, Malte Baron J, Neis M, al Masaoudi T, Merk HF. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 2002; 32: 736-744.
15. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. Soluble Fas and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997: 40: 1126-1129.
16. Rose LM, Latchman DS, Isenberg DA. Elevated soluble Fas production in SLE correlates with HLA status not with disease activity. Lupus 1997; 6: 717-722.
17. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.